Sensyne Health PLC (LON:SENS) said it appointed David Ruau to the newly created role of chief scientific officer with effect from September 1.
The ethical artificial intelligence (AI) firm said Ruau will lead the company’s research effort aimed at applying ethical AI to improve patient care and discover and develop new medicines.
READ: Sensyne Health mulls second listing on Nasdaq
Ruau joins the company from German pharma giant Bayer, where he served as head of global data assets and decision science and led teams working on the development and application of AI solutions in oncology, radiology and women's health.
Before joining Bayer, Ruau worked as head of scientific computing solutions at AstraZeneca PLC (LON:AZN) where he focused on data science solutions in the late-phase development pipeline to improve efficiency in designing and analysing clinical trials.
"I am thrilled to be joining Sensyne at such an exciting time for the business and for the pharmaceutical AI sector. The ethical application of AI to improve healthcare for patients and life sciences research is one of my greatest passions. Sensyne has a unique model that offers the potential to transform pharmaceutical development and I am greatly looking forward to joining the team", Ruau said in a statement.
"With his wealth of experience in bioinformatics, pharma and data science, I am delighted to welcome David to Sensyne. His experience will be invaluable as we continue to innovate and develop our work applying ethical AI to improve patient care and to accelerate the development of new medicines", added Sensyne chief executive Paul Drayson.